Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.47 |
| ▸ | AHCY | P23526 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14440925 | 0.90 | TYMP (0.42) | TYMPEHMT1ADORA3AHCYSLC29A1 | |
| SCHEMBL14440203 | 0.89 | TYMP (0.43) | TYMPEHMT1ADORA3AHCYSLC29A1 | |
| SCHEMBL14440221 | 0.89 | EHMT1 (0.62) | EHMT1ADORA3AHCYSLC29A1P2RX3 | |
| SCHEMBL14440224 | 0.89 | EHMT1 (0.62) | EHMT1ADORA3AHCYSLC29A1P2RX3 | |
| SCHEMBL14440629 | 0.84 | ADK (0.47) | — | |
| SCHEMBL14440208 | 0.83 | P2RX3 (0.51) | TYMPAHCYSLC29A1P2RX3P2RX2 | |
| SCHEMBL10590849 | 0.82 | EHMT1 (0.66) | EHMT1ADORA3AHCYSLC29A1RXFP1 | |
| SCHEMBL14440206 | 0.81 | TYMP (0.36) | TYMPEHMT1ADORA3AHCYSLC29A1 | |
| SCHEMBL14568433 | 0.81 | HIF1A (0.39) | TYMPEHMT1ADORA3AHCY | |
| SCHEMBL14440609 | 0.81 | HIF1A (0.39) | TYMPEHMT1ADORA3AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | TYMP 148/4885EHMT1 2870/4885ADORA3 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.